Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010015/S590

Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

Medtronic, Inc. · Decision date Oct 5, 2026

MEDTECHLEDGER EXPLANATIONP010015/S590

What did the FDA decide?

The FDA record lists PMA supplement P010015/S590 for the Percepta and Serena bipolar and quadripolar CRT-P and Solara bipolar CRT-P devices, with an OK30 decision dated 2026-10-05. The supplement is a 30-Day Notice filed under process change for manufacturer, sterilizer, packager or supplier, and the stated purpose is process and equipment updates in the manufacturing of MR Delta 26H3 batteries used in Medtronic CRM devices.

The identifier ties S590 to the original P010015 approval, so this is a supplement to that file rather than a separate approval of the full system. The notice covers the battery manufacturing step described in the statement; it does not set out which process parameters or equipment changed, any supporting data, or the basis for the decision, and it is not independent proof of safety or clinical effectiveness.

FDA approval order statement

process and equipment updates of the manufacturing process of MR Delta 26H3 batteries used in Medtronic CRM devices
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 5, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010015/S590
Regulatory pathway
PMA supplement
Product code
LWP
Decision code
OK30
Decision date
Oct 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010015 · Original PMA

    MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM

  2. P010015/S590 received

    Application receipt date recorded by FDA.

  3. P010015/S590 · FDA decision

    30-Day Notice

  4. P010015/S591 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  5. P010015/S592 · Related supplement

    Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010015

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records